How Much Does Actos (Pioglitazone) Cost in Pennsylvania in 2026?

Pennsylvania Cash Prices for Pioglitazone in 2026

The average cash price for a 30-day supply of generic pioglitazone across Pennsylvania retail pharmacies is roughly $15 in 2026. That figure applies to the most commonly prescribed strength (30 mg once daily) and can vary by $5 to $10 depending on pharmacy location, chain vs. Independent status, and whether a discount card is used.

How Brand vs. Generic Pricing Compares

Brand-name Actos carries a manufacturer list price near $60 per month from Takeda. Generic pioglitazone, available from manufacturers including Teva, Mylan, and Aurobindo, undercuts that price by approximately 75%. Because pioglitazone lost patent exclusivity in 2012, generic competition has driven prices steadily downward for over a decade 1.

Price Variation Across PA Pharmacies

Within Pennsylvania, prices differ between Philadelphia metro pharmacies and rural western PA locations. A 2024 analysis of Medicare Part D claims found that oral diabetes medications showed up to 40% price variation between the highest-cost and lowest-cost pharmacies within a single state 2. Checking prices at two or three pharmacies (or using a price comparison tool) before filling is a practical way to reduce out-of-pocket spending.

The 45 mg Dose Costs More

Pioglitazone 45 mg tablets typically cost 10% to 20% more than the 30 mg strength at most PA pharmacies, even though the clinical dose increase is modest. Ask your prescriber whether 30 mg provides adequate glycemic control before stepping up. The FDA-approved labeling notes that HbA1c reductions with 30 mg and 45 mg differ by only 0.3% on average.

Pennsylvania Medicaid Coverage for Pioglitazone

Pennsylvania Medicaid (Medical Assistance) covers pioglitazone as part of its preferred drug list for type 2 diabetes, though a prior authorization is required. The PA Department of Human Services manages formulary decisions through its pharmacy benefits contractor, and pioglitazone falls under the thiazolidinedione class.

What Prior Authorization Involves

Prior authorization for pioglitazone in PA Medicaid typically requires documentation that the patient has tried or cannot tolerate metformin. Prescribers submit the PA request electronically, and turnaround is generally 24 to 72 hours. Emergency supplies of up to 72 hours are available at the pharmacy while the PA is processed, per Pennsylvania Medicaid pharmacy policy.

Medicaid Managed Care Plans in PA

Most Pennsylvania Medicaid enrollees receive benefits through managed care organizations (MCOs) such as UPMC for You, Highmark Wholecare, AmeriHealth Caritas, and Aetna Better Health. Each MCO maintains its own formulary tier placement for pioglitazone, but all must cover at least one thiazolidinedione under federal Medicaid requirements. Co-pays for generic preferred drugs under PA Medicaid MCOs are typically $1 to $3.

Insurance Coverage for Pioglitazone in Pennsylvania

Private insurers in Pennsylvania almost universally cover generic pioglitazone, placing it on Tier 1 or Tier 2 of their formularies. Brand-name Actos, where still stocked, sits on Tier 3 (non-preferred brand) at most plans.

Employer-Sponsored Plans

Large employer plans in Pennsylvania from carriers like Independence Blue Cross, Highmark, UPMC Health Plan, and Geisinger Health Plan typically assign generic pioglitazone a co-pay of $5 to $15 per month. Some high-deductible health plans (HDHPs) require patients to pay cash price until the deductible is met, but pioglitazone's low generic cost means the out-of-pocket impact stays modest even pre-deductible.

ACA Marketplace Plans

Pennsylvania ACA marketplace plans sold through Pennie (the state exchange) follow Essential Health Benefit requirements that mandate coverage of at least one drug per pharmacologic class. Generic pioglitazone meets this requirement for thiazolidinediones. Silver-tier plans with cost-sharing reductions bring co-pays for Tier 1 generics down to $0 to $5 in many cases.

Medicare Part D in Pennsylvania

Medicare Part D plans available to PA residents cover generic pioglitazone on preferred tiers. Under the Inflation Reduction Act provisions now fully implemented, Medicare Part D out-of-pocket costs are capped at $2,000 annually 3. For a medication costing $15 per month, pioglitazone alone would never approach that cap. Most Part D plans in PA charge $0 to $10 co-pays for Tier 1 generics.

Clinical Value: Why Pioglitazone Remains Prescribed

Pioglitazone is a thiazolidinedione (TZD) that improves insulin sensitivity in muscle, adipose tissue, and the liver. Its clinical profile goes beyond glycemic control.

Glycemic Efficacy

In the PROactive trial (N=5,238), pioglitazone reduced HbA1c by 0.8% compared to placebo over a mean follow-up of 34.5 months 4. The drug works independently of beta-cell function, making it useful in patients with longstanding type 2 diabetes where sulfonylurea response has waned.

NASH/MASLD Evidence

The PIVENS trial (N=247) randomized non-diabetic adults with biopsy-confirmed NASH to pioglitazone 30 mg, vitamin E 800 IU, or placebo for 96 weeks. Pioglitazone produced histologic improvement in NASH in 34% of subjects vs. 19% on placebo, though this did not meet the prespecified significance threshold for the primary endpoint. Pioglitazone did significantly reduce hepatic steatosis, lobular inflammation, and insulin resistance 5.

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance states: "Pioglitazone may be used to treat biopsy-proven NASH in patients with and without type 2 diabetes" 6. Dr. Arun Sanyal, lead author of the PIVENS trial and professor of gastroenterology at Virginia Commonwealth University, has noted that "pioglitazone remains one of the few pharmacologic agents with randomized controlled trial evidence of histologic benefit in NASH."

Cardiovascular Considerations

A 2017 meta-analysis of 26 randomized trials (N=19,645) published in Diabetes Care found pioglitazone associated with a 17% relative risk reduction in major adverse cardiovascular events (MACE) among patients with insulin resistance or type 2 diabetes (HR 0.83, 95% CI 0.72 to 0.97, P=0.02) 7. This cardiovascular signal is relevant for prescribers weighing pioglitazone against newer, more expensive agents.

Discount Programs and Savings Cards in Pennsylvania

Several pathways exist to reduce pioglitazone costs further for PA residents, even below the $15 average.

Manufacturer and Generic Savings Programs

Takeda's branded Actos savings card is largely irrelevant for most patients because generic pioglitazone already costs less than any co-pay reduction the card provides. Generic manufacturers do not typically offer direct-to-consumer savings cards, but pharmacy benefit managers (PBMs) frequently negotiate rebates that keep generic TZD co-pays at $0 for many commercial plans.

Pharmacy Discount Cards

GoodRx, RxSaver, and similar discount platforms list pioglitazone 30 mg (30 tablets) at $4 to $12 across Pennsylvania pharmacies as of May 2026. These prices sometimes beat insurance co-pays, so it is worth comparing the discount card price against your plan's co-pay at pickup. Mark Cuban Cost Plus Drugs offers pioglitazone at a flat manufacturer cost plus 15% markup plus $5 dispensing fee, which brings prices under $10 for a 30-day supply.

$4 Generic Lists

Several major chains operating in Pennsylvania (Walmart, Costco, Giant Eagle) include pioglitazone on their $4 generic prescription lists for a 30-day supply. No insurance card is needed; simply present the prescription and request the $4 pricing at the pharmacy counter.

Compounded Pioglitazone in Pennsylvania

Compounded pioglitazone is available through 503A-licensed compounding pharmacies in Pennsylvania. State law permits 503A compounding pursuant to a valid patient-specific prescription, following both Pennsylvania Board of Pharmacy regulations and FDA guidance under Section 503A of the Federal Food, Drug, and Cosmetic Act 8.

When Compounding Might Apply

Compounded pioglitazone is rarely necessary given the wide availability and low cost of commercial tablets. Potential scenarios include patients who need a non-standard dose (e.g., 7.5 mg or 22.5 mg), those who require a liquid suspension due to dysphagia, or patients with specific excipient allergies not accommodated by commercial formulations. Compounded versions may cost $0 to $20 depending on the pharmacy, but insurance typically does not cover compounded products.

Finding a 503A Pharmacy in PA

The Pennsylvania Board of Pharmacy maintains a list of licensed compounding pharmacies. The Pharmacy Compounding Accreditation Board (PCAB) also provides a searchable directory filtered by state. Confirm that any 503A pharmacy you use holds current state licensure and follows USP 795 standards for non-sterile compounding.

Telehealth Access to Pioglitazone in Pennsylvania

Pennsylvania permits telehealth prescribing of pioglitazone with no in-person visit requirement for the initial prescription. State telehealth parity laws enacted in 2020 (Act 15) and extended through subsequent legislation require insurers to cover telehealth visits at the same rate as in-person encounters.

How Telehealth Prescribing Works

A licensed prescriber (physician, CRNP, or PA-C) conducts a synchronous video or audio visit, reviews labs (HbA1c, liver function tests, CBC), and writes the pioglitazone prescription electronically to any PA-licensed pharmacy. Baseline liver function testing is recommended before initiation per the FDA label, and ALT should be monitored periodically.

Telehealth Platforms Serving PA

Multiple telehealth platforms prescribe pioglitazone to Pennsylvania residents, including HealthRX, Cerebral, PlushCare, and Amazon Clinic. Visit costs range from $0 (with insurance) to $75 (cash pay, no insurance). Because pioglitazone is not a controlled substance, prescribing restrictions are minimal compared to stimulants or opioids.

Safety Monitoring and Cost Implications

Pioglitazone requires periodic lab monitoring that adds to the total cost of therapy, though the tests themselves are inexpensive.

Required and Recommended Labs

The FDA label recommends liver function tests (ALT) before starting pioglitazone and periodically thereafter. A basic metabolic panel or comprehensive metabolic panel (typically $10 to $25 at Quest or Labcorp in PA with insurance) covers this. HbA1c testing every 3 to 6 months ($20 to $50 without insurance) tracks glycemic response.

Black Box Warning: Heart Failure

Pioglitazone carries a black box warning for congestive heart failure risk due to fluid retention 1. The PROACTIVE trial found a 6% incidence of serious heart failure in the pioglitazone arm vs. 4% in the placebo arm 4. Patients with NYHA Class III or IV heart failure should not use pioglitazone. This does not affect cost, but it shapes which patients benefit from its low price point.

Bladder Cancer Signal

A 2016 updated meta-analysis in the BMJ (N=1,010,755 across 4 cohort studies and 3 nested case-control studies) found a modestly elevated bladder cancer risk with pioglitazone use exceeding 2 years (RR 1.40, 95% CI 1.15 to 1.71) 9. The FDA reviewed this signal and retained pioglitazone's approval with label updates rather than withdrawal, concluding that the absolute risk increase remains small. Prescribers in PA should discuss this finding with patients during shared decision-making.

How Pennsylvania Compares to Neighboring States

Pennsylvania's average $15 per month cash price for generic pioglitazone tracks closely with New Jersey ($14), Delaware ($13), and Ohio ($16), based on 2026 pharmacy claims aggregates. New York tends to run $2 to $4 higher due to higher pharmacy dispensing fees. West Virginia Medicaid covers pioglitazone without prior authorization, a slightly easier pathway than PA's PA requirement.

The American Diabetes Association's 2024 Standards of Care recommend considering cost when selecting glucose-lowering therapy, noting that "thiazolidinediones are among the lowest-cost oral agents available" 10.